The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today adopted a positive opinion on a license extension for UCB’s epilepsy medicine...
UCB (Union Chimique Belge) is een pharmaceutische wereldspeler. UCB is actief in 40 landen en telt meer dan 7500 werknemers. Het bedrijf haalde een omzet van 3,88 miljard euro in 2015.
Het bedrijf
Investor Relations
Kerncijfers
BRIVIACT® now available in U.S. pharmacies for epilepsy patients living with partial-onset seizures
Today UCB announced that BRIVIACT®(brivaracetam) CV, approved as adjunctive therapy for the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy,...
UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016)
UCB, a global biopharmaceutical company focusing on immunology, neurology and bone treatment and research, is proud to present pivotal, long-term data on Cimzia® (certolizumab...
UCB’s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis
UCB today presented results from a Phase 1B study evaluating pharmacokinetics, safety, tolerability and preliminary efficacy of multiple doses of bimekizumab in patients with psoriatic...
UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT®) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy
Daiichi Sankyo Company, Limited ("Daiichi Sankyo"; TSE: 4568) and UCB Biopharma SPRL ("UCB") today announced the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for...
UCB and Amgen submit biologics license application for Romosozumab to the U.S. FDA
UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an...
UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting
UCB (Euronext Brussels: UCB) and Amgen (NASDAQ: AMGN) today announced that they are presenting Phase 3 data for the investigational agent romosozumab at the annual meeting of the American...
UCB receives positive EU CHMP opinion for CIMZIA® (certolizumab pegol) AutoClicks® Prefilled Pen
UCB has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of...
UCB and Amgen announce U.S. FDA acceptance of biologics licence application for Romosozumab
UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for...
CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
UCB (Euronext: UCB) and Dermira, Inc. (NASDAQ: DERM) today announced topline results from CIMPASI-2, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and...